MedTrace Logo

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

NCT03210740 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-04-30

No results posted yet for this study

Summary

To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of Actinic Keratosis (AK) Lesions

Conditions

  • Actinic Keratosis

Interventions

DRUG

AM001 Cream, 7.5%

Active Cream

DRUG

Vehicle Cream

Placeo

Sponsors & Collaborators

  • AmDerma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2018-02-13
Completion
2018-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03210740 on ClinicalTrials.gov